Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns (Q34206910)

31 July 2017

1 reference

title

Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns (English)

1 reference

31 July 2017

1 reference

3

Mark Wainberg

1 reference

31 July 2017

1

Julianna Lisziewicz

1 reference

31 July 2017

Andrea Foli

2

1 reference

31 July 2017

Franco Lori

series ordinal

4

1 reference

31 July 2017

publication date

1 January 2003

1 reference

31 July 2017

1 reference

31 July 2017

volume

26

1 reference

31 July 2017

issue

9

1 reference

31 July 2017

page(s)

605-624

1 reference

Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection

31 July 2017

cites work

1 reference

12 December 2020

Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging

1 reference

12 December 2020

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients

1 reference

12 December 2020

In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.

1 reference

12 December 2020

Hydroxyurea as part of a salvage regimen for heavily pretreated patients with advanced HIV infection

1 reference

12 December 2020

Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus

1 reference

12 December 2020

The Alpha trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease. Alpha International Coordinating Committee

1 reference

12 December 2020

A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.

1 reference

12 December 2020

Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide

1 reference

12 December 2020

Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor

1 reference

12 December 2020

Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication

1 reference

12 December 2020

Studies in subjects with long-term nonprogressive human immunodeficiency virus infection

1 reference

12 December 2020

An overview of the clinical experience with hydroxyurea

1 reference

12 December 2020

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1 reference

12 December 2020

Comparative distribution and embryotoxicity of hydroxyurea in pregnant rats and rhesus monkeys

1 reference

12 December 2020

Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression

1 reference

12 December 2020

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

12 December 2020

Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters

1 reference

12 December 2020

Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients

1 reference

12 December 2020

Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease

1 reference

12 December 2020

Targeting HIV reservoirs and reconstituting the immune system. Second annual meeting Research Institute for Genetic and Human Therapy April 18-19, 1999 Washington, DC.

1 reference

12 December 2020

Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes

1 reference

12 December 2020

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

12 December 2020

Short-term anti-HIV activity of the combination of didanosine and hydroxyurea

1 reference

12 December 2020

Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance

1 reference

12 December 2020

No therapeutic advantage from didanosine (ddI) and hydroxyurea versus ddI alone in patients with HIV infection

1 reference

12 December 2020

Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy

1 reference

12 December 2020

Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression

1 reference

12 December 2020

A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group

1 reference

12 December 2020

Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes

1 reference

12 December 2020

Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.

1 reference

12 December 2020

Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication

1 reference

12 December 2020

Clinical use of hydroxyurea in HIV-1 infected patients

1 reference

12 December 2020

Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection

1 reference

12 December 2020

HYDROXYUREA (NSC-32065): RESULTS OF A PHASE I STUDY

1 reference

12 December 2020

A phase I study of hydroxyurea

1 reference

12 December 2020

Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor

1 reference

12 December 2020

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

12 December 2020

Long-term cultures of HTLV-III--infected T cells: a model of cytopathology of T-cell depletion in AIDS.

1 reference

12 December 2020

Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine

1 reference

12 December 2020

Hydroxyurea: mechanisms of HIV-1 inhibition.

1 reference

12 December 2020

Hydroxyurea-induced hepatitis in human immunodeficiency virus-positive patients

1 reference

12 December 2020

Hydroxyurea toxicity in human immunodeficiency virus-positive patients

1 reference

12 December 2020

Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir

1 reference

12 December 2020

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia

1 reference

12 December 2020

Correlates of protective viruses damaging to HIV infection

1 reference

12 December 2020

Hydroxyurea and AIDS: an old drug finds a new application?

1 reference

12 December 2020

Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.

1 reference

12 December 2020

Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals

1 reference

12 December 2020

HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure

1 reference

12 December 2020

Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus

1 reference

12 December 2020

Acute pancreatitis as a common complication of 2',3'-dideoxyinosine therapy in the acquired immunodeficiency syndrome

1 reference

12 December 2020

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy

1 reference

12 December 2020

Effects of hydroxyurea on T cell count changes during primary HIV infection

1 reference

12 December 2020

Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors.

1 reference

12 December 2020

Direct analysis of mitochondrial toxicity of antiretroviral drugs

1 reference

12 December 2020

Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs

1 reference

12 December 2020

Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides

1 reference

12 December 2020

Hydroxyurea and HIV: 5 years later--from antiviral to immune-modulating effects

1 reference

12 December 2020

HIV-1 replication is controlled at the level of T cell activation and proviral integration

1 reference

12 December 2020

Immune Restoration by Combination of a Cytostatic Drug (Hydroxyurea) and Anti-HIV Drugs (Didanosine and Indinavir)

1 reference

12 December 2020

Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection

1 reference

12 December 2020

A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study

1 reference

12 December 2020

Hydroxyurea treatment in HIV-infected patients

1 reference

12 December 2020

Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study

1 reference

12 December 2020

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

1 reference

12 December 2020

Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine

1 reference

12 December 2020

1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection

1 reference

12 December 2020

Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates

1 reference

12 December 2020

Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea

1 reference

12 December 2020

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway

1 reference

12 December 2020

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Lymphoproliferative response to HIV type 1 p24 in long-term survivors of HIV type 1 infection is predictive of persistent AIDS-free infection

1 reference

12 December 2020

T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS.

1 reference

12 December 2020

10.2165/00002018-200326090-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1007574081

0 references

1 reference